Cytosorbents Corporation (CTSO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 0.44 |
| Open | 0.43 |
| Day High | 0.43 |
| Day Low | 0.41 |
| 52-Week High | 1.39 |
| 52-Week Low | 0.37 |
| Volume | 47,324 |
| Average Volume | 149,503 |
| Market Cap | 25.93M |
| PE | -2.29 |
| EPS | -0.18 |
| Moving Average 50 Days | 0.54 |
| Moving Average 200 Days | 0.7 |
| Change | -0.03 |
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
GlobeNewswire Inc.
Mar 04, 2025 12:00 PM GMT
The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025PRINCETON, N.J., March 04, 202
CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
GlobeNewswire Inc.
Feb 26, 2025 12:00 PM GMT
PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter
CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants
GlobeNewswire Inc.
Feb 25, 2025 12:00 PM GMT
1,417,208 Series A Right Warrants Exercised at $1.13 Per Share, Providing $1.6 Million in Aggregate Gross ProceedsPRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threaten